Kelly Harris
Nurse Practitioner · Milan, GANPI 1275210510
Payments from drug & device makers
Across 37 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$100
- AstraZeneca$74
- Pfizer$49
- Novartis$49
- Lilly USA, LLC$46
- Merck$45
- plus $399 from 16 others
What the payments were for
- Food & beverage$762100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 4 | $100 |
| AstraZeneca(2 entities) | 4 | $74 |
| Pfizer | 2 | $49 |
| Novartis | 3 | $49 |
| Lilly USA, LLC | 2 | $46 |
| Merck | 2 | $45 |
| Genentech USA, Inc. | 2 | $41 |
| Array Biopharma Inc | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Kerecis Limited | 3 | $32 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Bayer | 1 | $22 |
| Solventum Corporation | 1 | $22 |
| Integra Lifesciences Corporation | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Mimedx Group, Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Exelixis Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
How this compares
$762 in reported general payments places this provider in the 70th percentile of 3,328 nurse practitioner providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $11,831 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,269 |
| Celecoxib | 14 | $206 |
| Gabapentin | 11 | $176 |
| Atorvastatin Calcium | 47 | $162 |
| Levothyroxine Sodium | 24 | $154 |
| Levetiracetam | 17 | $136 |
| Glimepiride | 19 | $123 |
| Amlodipine Besylate | 41 | $115 |
| Fluticasone Propionate | 13 | $110 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 14 | $90 |
| Losartan Potassium | 15 | $69 |
| Lisinopril | 13 | $58 |
| Pantoprazole Sodium | 13 | $41 |
| Hydrochlorothiazide | 13 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $46 | $11,83111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Milan
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.